Loading...
XNASIRIX
Market cap26mUSD
Jan 14, Last price  
1.61USD
1D
-1.22%
1Q
1.45%
Jan 2017
-88.53%
Name

IRIDEX Corp

Chart & Performance

D1W1MN
XNAS:IRIX chart
P/E
—
P/S
0.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.74%
Rev. gr., 5y
4.02%
Revenues
52m
-8.96%
32,810,00037,029,00035,904,00055,532,00048,528,00043,212,00043,694,00033,159,00033,859,00038,273,00042,814,00041,757,00046,158,00041,593,00042,600,00043,447,00036,347,00053,903,00056,972,00051,869,000
Net income
-10m
L+26.81%
-402,0001,671,000-5,753,000-22,272,000-7,370,0002,585,0003,046,0002,610,0001,438,0002,231,00010,038,000474,000-11,713,000-12,867,000-12,813,000-8,813,000-6,329,000-5,225,000-7,547,000-9,570,000
CFO
-7m
L-29.14%
771,0002,770,000-1,385,000-522,000-96,0006,798,0003,479,0003,048,000-443,000767,0004,014,000-593,000-144,000-3,565,000-10,025,000-7,913,000-3,237,0008,217,000-9,519,000-6,745,000
Earnings
Mar 24, 2025

Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
URL
https://www.iridex.com/
IPO date
Feb 16, 1996
Employees
130
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122022‑002021‑002019‑122018‑122017‑122016‑122016‑00
Income
Revenues
51,869
-3.77%
56,972
56.74%
Cost of revenue
61,876
64,514
Unusual Expense (Income)
NOPBT
(10,007)
(7,542)
NOPBT Margin
Operating Taxes
90
65
Tax Rate
NOPAT
(10,097)
(7,607)
Net income
(9,570)
83.16%
(7,547)
19.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
(5)
9,784
BB yield
0.01%
-30.54%
Debt
Debt current
1,990
1,037
Long-term debt
6,248
2,501
Deferred revenue
10,025
11,742
Other long-term liabilities
(1,587)
132
Net debt
1,204
(10,384)
Cash flow
Cash from operating activities
(6,745)
(9,519)
CAPEX
(109)
(286)
Cash from investing activities
(109)
(286)
Cash from financing activities
(5)
(73)
FCF
(12,937)
(10,575)
Balance
Cash
7,034
13,922
Long term investments
Excess cash
4,441
11,073
Stockholders' equity
(78,922)
(69,571)
Invested Capital
104,125
100,380
ROIC
ROCE
EV
Common stock shares outstanding
16,128
15,938
Price
2.81
-54.01%
2.01
-19.92%
Market cap
45,320
-51.90%
32,035
-7.79%
EV
46,524
21,651
EBITDA
(7,975)
(6,158)
EV/EBITDA
Interest
1,444
Interest/NOPBT